Sonendo (SONX) 10-Q 9 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 02, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	Sonendo, Inc.
Entity Central Index Key	0001407973
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Small Business	true
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		49,756,666
Entity File Number	001-40988
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5041718
Entity Address, Address Line One	26061 Merit Circle
Entity Address, Address Line Two	Suite 102
Entity Address, City or Town	Laguna Hills
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92653
City Area Code	949
Local Phone Number	766-3636
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	SONX
Security Exchange Name	NYSE

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 68,512	$ 84,641
Short-term investments	37,074
Accounts receivable, net	3,349	2,516
Inventory	15,185	8,150
Prepaid expenses and other current assets	2,911	3,552
Total current assets	127,031	98,859
Property and equipment, net	2,739	2,366
Operating lease right-of-use assets	2,140	2,746
Intangible assets, net	2,458	2,956
Goodwill	8,454	8,454
Other assets	118	118
Total assets	142,940	115,499
Current liabilities:
Accounts payable	2,057	3,061
Accrued expenses	5,098	4,758
Accrued compensation	3,959	3,376
Operating lease liabilities	982	975
Other current liabilities	2,249	2,482
Total current liabilities	14,345	14,652
Operating lease liabilities, net of current	1,121	1,730
Term loan, net of current	36,599	26,496
Other liabilities	519	558
Total liabilities	52,584	43,436
Commitments and contingencies (Note 8)
Stockholders' deficit:
Preferred stock, $0.001 par value; authorized -10,000,000 shares; issued and outstanding - none
Common stock, $0.001 par value; authorized - 500,000,000 shares; issued - 49,803,355 shares as of September 30, 2022 and 26,383,225 shares as of December 31, 2021; outstanding - 49,756,666 shares as of September 30, 2022 and 26,336,536 shares as of December 31, 2021	50	26
Additional paid-in-capital	448,648	384,132
Accumulated other comprehensive loss	(49)
Accumulated deficit	(358,242)	(312,044)
Stockholders' deficit before treasury stock	90,407	72,114
Less: Treasury stock	(51)	(51)
Total stockholders' equity	90,356	72,063
Total liabilities and stockholders' equity	$ 142,940	$ 115,499

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	49,803,355	26,383,225
Common stock, shares outstanding	49,756,666	26,336,536

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenue	$ 9,846	$ 7,887	$ 29,426	$ 23,306
Cost of sales	7,528	5,838	22,276	17,422
Gross profit	2,318	2,049	7,150	5,884
Operating expenses:
Selling, general and administrative	12,586	8,495	37,393	22,400
Research and development	4,328	4,633	13,196	14,310
Change in fair value of contingent earnout		19		12
Total operating expenses	16,914	13,147	50,589	36,722
Loss from operations	(14,596)	(11,098)	(43,439)	(30,838)
Interest and financing costs, net	(943)	(1,076)	(2,759)	(3,224)
Change in fair value of warrant liabilities		(159)		(176)
Change in fair value of forward obligation		(400)		(550)
Loss before income tax expense	(15,539)	(12,733)	(46,198)	(34,788)
Net loss	(15,539)	(12,733)	(46,198)	(34,788)
Other comprehensive loss (net of tax):
Unrealized loss on marketable securities	(7)		(49)
Net comprehensive loss	$ (15,546)	$ (12,733)	$ (46,247)	$ (34,788)
Net loss per share attributable to common stock - basic	$ (0.47)	$ (10.33)	$ (1.61)	$ (28.54)
Net loss per share attributable to common stock - diluted	$ (0.47)	$ (10.33)	$ (1.61)	$ (28.54)
Weighted-average shares outstanding - basic	33,116,536	1,232,921	28,688,018	1,218,815
Weighted-average shares outstanding - diluted	33,116,536	1,232,921	28,688,018	1,218,815
Product
Total revenue	$ 7,795	$ 6,186	$ 23,440	$ 18,166
Cost of sales	6,875	5,260	20,338	15,668
Gross profit	920	926	3,102	2,498
Operating expenses:
Selling, general and administrative	12,141	7,961	35,911	20,893
Research and development	3,891	4,214	11,874	13,075
Change in fair value of contingent earnout		19		12
Total operating expenses	16,032	12,194	47,785	33,980
Loss from operations	(15,112)	(11,268)	(44,683)	(31,482)
Software
Total revenue	2,051	1,701	5,986	5,140
Cost of sales	653	578	1,938	1,754
Gross profit	1,398	1,123	4,048	3,386
Operating expenses:
Selling, general and administrative	445	534	1,482	1,507
Research and development	437	419	1,322	1,235
Total operating expenses	882	953	2,804	2,742
Loss from operations	$ 516	$ 170	$ 1,244	$ 644

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Convertible Preferred Stock Beginning balance, Shares at Dec. 31, 2020		17,031,887
Convertible Preferred Stock Beginning balance at Dec. 31, 2020		$ 281,342
Beginning balance, Shares at Dec. 31, 2020			1,200,335
Beginning balance at Dec. 31, 2020	$ (253,891)		$ 2	$ (51)	$ 9,703		$ (263,545)
Exercise of stock options	33				33
Exercise of stock options, Shares			12,797
Stock-based compensation	494				494
Net loss	(10,906)						(10,906)
Convertible Preferred Stock Ending balance, Shares at Mar. 31, 2021		17,031,887
Convertible Preferred Stock Ending balance at Mar. 31, 2021		$ 281,342
Ending balance, Shares at Mar. 31, 2021			1,213,132
Ending balance at Mar. 31, 2021	(264,270)		$ 2	(51)	10,230		(274,451)
Convertible Preferred Stock Beginning balance, Shares at Dec. 31, 2020		17,031,887
Convertible Preferred Stock Beginning balance at Dec. 31, 2020		$ 281,342
Beginning balance, Shares at Dec. 31, 2020			1,200,335
Beginning balance at Dec. 31, 2020	(253,891)		$ 2	(51)	9,703		(263,545)
Net loss	(34,788)
Convertible Preferred Stock Ending balance, Shares at Sep. 30, 2021		17,031,887
Convertible Preferred Stock Ending balance at Sep. 30, 2021		$ 281,342
Ending balance, Shares at Sep. 30, 2021			1,258,945
Ending balance at Sep. 30, 2021	(287,056)		$ 2	(51)	11,326	$ (298,333)
Convertible Preferred Stock Beginning balance, Shares at Mar. 31, 2021		17,031,887
Convertible Preferred Stock Beginning balance at Mar. 31, 2021		$ 281,342
Beginning balance, Shares at Mar. 31, 2021			1,213,132
Beginning balance at Mar. 31, 2021	(264,270)		$ 2	(51)	10,230		(274,451)
Exercise of stock options	56				56
Exercise of stock options, Shares			10,214
Stock-based compensation	413				413
Net loss	(11,149)						(11,149)
Convertible Preferred Stock Ending balance, Shares at Jun. 30, 2021		17,031,887
Convertible Preferred Stock Ending balance at Jun. 30, 2021		$ 281,342
Ending balance, Shares at Jun. 30, 2021			1,223,346
Ending balance at Jun. 30, 2021	(274,950)		$ 2	(51)	10,699		(285,600)
Exercise of stock options	86				86
Exercise of stock options, Shares			35,599
Stock-based compensation	541				541
Net loss	(12,733)					(12,733)
Convertible Preferred Stock Ending balance, Shares at Sep. 30, 2021		17,031,887
Convertible Preferred Stock Ending balance at Sep. 30, 2021		$ 281,342
Ending balance, Shares at Sep. 30, 2021			1,258,945
Ending balance at Sep. 30, 2021	(287,056)		$ 2	(51)	11,326	(298,333)
Beginning balance, Shares at Dec. 31, 2021			26,336,536
Beginning balance at Dec. 31, 2021	72,063		$ 26	(51)	384,132		(312,044)
Employee stock plans	242				242
Employee stock plans, Shares			82,572
Stock-based compensation	1,394				1,394
Net loss	(15,522)						(15,522)
Ending balance, Shares at Mar. 31, 2022			26,419,108
Ending balance at Mar. 31, 2022	58,177		$ 26	(51)	385,768		(327,566)
Beginning balance, Shares at Dec. 31, 2021			26,336,536
Beginning balance at Dec. 31, 2021	$ 72,063		$ 26	(51)	384,132		(312,044)
Exercise of stock options, Shares	71,199
Unrealized loss on short-term investments	$ (49)
Net loss	(46,198)
Ending balance, Shares at Sep. 30, 2022			49,756,666
Ending balance at Sep. 30, 2022	90,356		$ 50	(51)	448,648	(49)	(358,242)
Beginning balance, Shares at Mar. 31, 2022			26,419,108
Beginning balance at Mar. 31, 2022	58,177		$ 26	(51)	385,768		(327,566)
Employee stock plans	9		$ 1		8
Employee stock plans, Shares			150,112
Stock-based compensation	1,954				1,954
Revaluation of warrants	73				73
Unrealized loss on short-term investments	(42)					(42)
Net loss	(15,137)						(15,137)
Ending balance, Shares at Jun. 30, 2022			26,569,220
Ending balance at Jun. 30, 2022	45,034		$ 27	(51)	387,803	(42)	(342,703)
Employee stock plans	2				2
Employee stock plans, Shares			141,910
Issuance of common stock, net of issuance costs	20,568		$ 23		20,545
Issuance of common stock, net of issuance costs, shares			23,045,536
Issuance of pre-funded warrants, net of issuance costs	38,575				38,575
Stock-based compensation	1,723				1,723
Unrealized loss on short-term investments	(7)					(7)
Net loss	(15,539)						(15,539)
Ending balance, Shares at Sep. 30, 2022			49,756,666
Ending balance at Sep. 30, 2022	$ 90,356		$ 50	$ (51)	$ 448,648	$ (49)	$ (358,242)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (46,198)	$ (34,788)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	744	1,109
Amortization intangible assets	498	420
Amortization of right-of-use lease assets	829	726
Amortization of debt issuance costs	327	655
Stock-based compensation	5,071	1,448
Change in fair value of warrant liabilities		176
Loss on disposal of assets		2
Change in fair value of forward obligation		550
Change in fair value of contingent earnout		12
Other non-cash operating activities, net	(158)	113
Changes in operating assets and liabilities:
Accounts receivable, net	(833)	20
Inventory	(7,086)	(3,011)
Prepaid expenses and other assets	641	(575)
Accounts payable	(1,039)	20
Accrued expenses and other liabilities	(409)	(276)
Deferred revenue	204	(158)
Accrued compensation	583	(323)
Net cash used in operating activities	(46,826)	(33,880)
Cash flows from investing activities:
Purchases of available-for-sale securities	(45,664)
Proceeds from maturities of available-for-sale securities	8,700
Purchases of property and equipment	(1,031)	(485)
Acquisition of intangible assets		(1,297)
Net cash used in investing activities	(37,995)	(1,782)
Financing activities:
Proceeds from issuance of common stock, net of issuance costs	20,623
Proceeds from issuance of pre-funded warrants, net of issuance costs	38,722
Proceeds from debt, net of issuance costs	9,850
Issuance of stock under employee stock plans	252	175
Payment of common stock IPO issuance costs	(598)
Principal repayments on finance lease	(40)	(35)
Payment of contingent earnout	(117)	(667)
Payment of deferred offering costs		(1,335)
Deferred financing costs		450
Net cash provided by (used in) financing activities	68,692	(2,312)
Net decrease in cash and cash equivalents	(16,129)	(37,974)
Cash and cash equivalents at beginning of period	84,641	51,722
Cash and cash equivalents at end of period	68,512	13,748
Cash paid for:
Interest	2,804	2,577
Supplemental schedule of non-cash investing and financing activities:
Operating lease right-of-use assets obtained in exchange for lease liabilities	223	362
Lease liabilities recorded for operating lease right-of-use assets	$ (223)	(362)
Fair value of preferred stock warrants issued		2,134
Deferred offering costs included in accrued expenses		538
Unpaid deferred financing costs		$ 50

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Description of Business Sonendo, Inc. (“Sonendo” or the “Company”) was incorporated in June 2006 pursuant to the laws of the State of Delaware under the name Dentatek Corporation. In March 2011, the Company changed its name to Sonendo, Inc. The Company is a medical technology company that has developed and is commercializing the GentleWave System to treat tooth decay. The Company’s principal market is the United States. The Company’s products include the GentleWave System, which is cleared by the United States (“U.S.”) Food and Drug Administration (“FDA”) for sale in the U.S., along with the system’s sterilized, single-use procedure instruments ("PIs"). In addition, the Company offers practice management software to enable an integrated digital office for dental practitioners. Basis of Presentation The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (“SEC”) on a consistent basis with the Company’s annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments considered necessary for a fair statement of the Company’s financial information. Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. The results of operations included in these condensed consolidated financial statements are not necessarily indicative of the results of operations to be expected for the year, any other interim period, or for any other future annual or interim period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed, consolidated, or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 23, 2022. Initial Public Offering and Reverse Stock Split On October 20, 2021, the Company’s Board of Directors (the "Board") approved an amendment to the Company’s certificate of incorporation to effect a reverse split of shares of the Company’s common stock and convertible preferred stock on a 1-for- 1.825 basis (the “Reverse Stock Split”). The par values of the common stock and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All references to common stock, options to purchase common stock, convertible preferred stock, warrants and forward obligation issued for preferred stock, share data, per share data and related information contained in the unaudited condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The Reverse Stock Split was effected on October 22, 2021. On November 2, 2021, the Company completed its initial public offering (“IPO”) of 7.8 million shares of its common stock at a public offering price of $ 12.00 per share. The aggregate net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses, were $ 83.8 million . On November 2, 2021, the Company amended and restated its certificate of incorporation to provide for, among other things, the Company’s authorized capital stock to consist of 500,000,000 shares of common stock, par value $ 0.001 per share, and 10,000,000 shares of preferred stock, par value $ 0.001 per share. In addition, upon the closing of the IPO, all 17,031,887 outstanding shares of the Company’s convertible preferred stock were converted into an equal number of shares of common stock, 224,842 shares of common stock were issued in connection with the settlement of the outstanding forward obligation and warrants to purchase 331,503 shares of convertible preferred stock were converted into equal number of warrants to purchase shares of common stock. The amended and restated certificate of incorporation defines the voting rights, dividends, liquidation, rights and preferences of each class of stock. Private Placement On September 27, 2022, the Company completed a private placement (the "Private Placement"), issuing an aggregate of 23.0 million shares of its common stock at a purchase price of $ 0.95 per share and pre-funded warrants to purchase an aggregate of 43.3 million shares of common stock at a purchase price of $ 0.949 per pre-funded warrant. The pre-funded warrants have an exercise price of $ 0.001 per share of common stock, are immediately exercisable and will remain exercisable until exercised in full. The aggregate net proceeds from the Private Placement, after deducting placement agent fees and other offering expenses, were $ 59.1 million . See Note 5, Convertible Preferred Stock and Common Stock , for additional information. Liquidity and Management’s Plans As of September 30, 2022, the Company had cash and cash equivalents of $ 68.5 million and short-term investments of $ 37.1 million . The Company has a limited operating history, and the revenue and income potential of the Company’s business and market are unproven. The Company has experienced net losses and negative cash flows from operations since its inception and as of September 30, 2022 had an accumulated deficit of $ 358.2 million . During the nine months ended September 30, 2022, the Company incurred net losses of $ 46.2 million and used $ 46.8 million of cash and cash equivalents in operations. The Company will continue to incur significant costs and expenses related to its ongoing operations until it gains market acceptance of its products and achieves a level of revenues adequate to support its operations. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Based on its current operating plan, the Company expects that its existing cash and cash equivalents and short-term investments, together with anticipated revenue and available debt financing arrangements, will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of the accompanying unaudited condensed consolidated financial statements. If the Company's actual operating expenses significantly exceed its operating plan or its debt financing arrangements become unavailable because certain borrowing requirements are not met (see Note 9), the Company may have to significantly delay or scale back its operations to reduce working capital requirements, and substantial uncertainty would exist with respect to the Company’s ability to continue as a going concern. In addition, the Company would prioritize necessary and appropriate steps to enable the continued operations of the business and preservation of the value of its assets beyond the next 12 months, including but not limited to, actions such as reducing personnel-related costs and delaying or curtailing the Company’s commercial efforts, development activities and other discretionary expenditures that are within the Company’s control. These reductions in expenditures, if required, may have an adverse impact on the Company’s ability to achieve certain of its planned objectives. COVID-19 The COVID-19 pandemic has negatively impacted the Company's operations, revenue and overall financial condition, and may negatively impact its operations, revenue, and overall financial condition in the future if new and more transmissible vaccine-resistant variants emerge. The Company's customers, including endodontists, have experienced significant financial hardship and some of them may never fully recover. The Company has also experienced disruptions, and may experience future disruptions, including: delays in capital and clinical sales representatives becoming fully trained and productive; difficulties and delays in dental practitioner outreach and training dental practitioners to use its GentleWave System; travel restrictions; delays in initiation, enrollment and follow-ups of its clinical studies; challenges with maintaining adequate supply from third-party manufacturers of components and finished goods and distribution providers; and access to dental practitioners for training and case support. The COVID-19 pandemic also resulted in, and may in the future result in, significant disruption to the global financial markets, reducing its ability to access capital, which could in the future negatively affect its liquidity. As of September 30, 2022, the COVID-19 pandemic d id not trig ger any asset impairments for the Company. The duration and ultimate economic impact of the COVID-19 pandemic on the Company's business remains uncertain at this time. The Company expects that any future restrictions on dental procedures, as a result of COVID-19 or the emergence of any vaccine resistant variant, and other related issues including supply chain disruptions, would have a negative impact on our operations, revenue and overall financial condition. Operating Segments The Company operates two operating and reportable segments: Product and Software. Operating segments are defined as components of an enterprise for which discrete financial information is available and evaluated regularly by the chief operating decision maker, who is the Company’s chief executive officer (“CEO”), for the purpose of allocating resources and assessing performance. Description of the activities within these segments is included in Note 12. Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to avail itself of this exemption and, therefore, for new or revised accounting standards applicable to public companies, the Company will be subject to an extended transition period until those standards would otherwise apply to private companies.

Summary Accounting Policies and

Summary Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary Accounting Policies and Recent Accounting Pronouncements	2. Summary Accounting Policies and Recent Accounting Pronouncements The accounting policies followed by the Company are set forth in Part II, Item 8, Note 2, Summary of Accounting Policies , of the Notes to Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make informed estimates, judgements and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and disclosures in the accompanying notes, including estimates of probable losses and expenses, as of the date of the accompanying unaudited condensed consolidated financial statements. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of these unaudited condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including the expected business and operational changes, the sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from the estimates and assumptions used in the preparation of the accompanying unaudited condensed consolidated financial statements under different assumptions or conditions. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include U.S. Treasury bills, deposits, money market funds and commercial paper. Short-Term Investments Short-term investments consist of available-for-sale U.S. Treasury securities, U.S. government agency securities, corporate bonds and commercial paper with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company’s condensed consolidated statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments. Revenue Recognition Contracts with Customers The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Specifically, the Company applies the following five core principles to recognize revenue: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies a performance obligation. Product revenue is generated from sales of the GentleWave console and related PIs and accessories. Software revenue is generated from sales of The Digital Office ("TDO") endodontist practice management software licenses. The Company’s products are sold primarily in the United States and Canada directly to customers through its field sales force. Performance Obligations The Company’s performance obligations primarily arise from the manufacture and delivery of the GentleWave System, related PIs and accessories, and the delivery or license of TDO software and related ancillary services. Payment terms are typically on open credit terms consistent with industry practice and do not have significant financing components. Consideration may be variable based on volume. The Company considers the individual deliverables in its product offering as separate performance obligations and assesses whether each promised good or service is distinct. The total contract transaction price is determined based on the consideration expected to be received, based on the stated value in contractual arrangements or the estimated cash to be collected in no-contracted arrangements, and is allocated to the identified performance obligations based upon the relative standalone selling prices of the performance obligations. The stand-alone selling price is based on an observable price offered to other comparable customers. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer and market conditions. The Company regularly reviews and updates standalone selling prices as necessary. The consideration the Company receives in exchange for its goods or services is only recognized when it is probable that a significant reversal will not occur. The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration. The Company estimates related variable consideration at the point of sale, including discounts, product returns, refunds, and other similar obligations. Revenue is recognized over time when the customer simultaneously receives and consumes the benefits provided by the Company’s performance. Revenue is recognized at a point in time if the criteria for recognizing revenue over time are not met, and the Company has transferred control of the goods to the customer. Product revenue is recognized at a point in time when the Company has transferred control to the customer, which is generally when title of the goods transfers to the customer. Software is licensed via delivery to the customer or via a service arrangement under which cloud-based access is provided on a subscription basis (software-as-a-service). When a fixed up-front license fee is received in exchange for the delivery of software, revenue is recognized at the point in time when the delivery of the software has occurred. When software is licensed on a subscription basis, revenue is recognized over the respective license period. The Company also sells extended service contracts on its GentleWave Systems. Sales of extended service contracts are recorded as deferred revenue until such time as the standard warranty expires, which is generally up to two years from the date of sale. Service contract revenue is recognized on a straight-line basis over time consistent with the life of the related service contract in proportion to the costs incurred in fulfilling performance obligations under the service contract. Revenue for technical support and other services is recognized ratably over the performance obligation period. The Company generally does not experience returns. If necessary, a provision is recorded for estimated sales returns and allowances and is deducted from gross product revenue to arrive at net product revenue in the period the related revenue is recorded. These estimates are based on historical sales returns and allowances and other known factors. Actual returns and claims in any future period are inherently uncertain and thus may differ from these estimates. If actual or expected future returns and claims are significantly greater or lower than the reserves established, a reduction or increase to revenue will be recorded in the period in which such a determination is made. All non-income government-assessed taxes (sales and use taxes) collected from the Company’s customers and remitted to governmental agencies are recorded in accrued expenses until they are remitted to the government agency. The Company has adopted the practical expedient permitting the direct expensing of costs incurred to obtain contracts where the amortization of such costs would occur over one year or less, and it applied to substantially all the Company’s contracts. Contract liabilities The Company recognizes a contract liability when a customer pays for goods or services for which the Company has not yet transferred control. The balances of the Company’s contract liabilities are as follows: As of September 30, December 31, 2022 2021 (in thousands) Extended service contracts $ 315 $ 251 Subscription software licenses 660 520 Total contract liabilities $ 975 $ 771 Contract liabilities are included within other current liabilities in the accompanying unaudited condensed consolidated balance sheets. Revenue recognized during the three months ended September 30, 2022 and 2021 that was included in the contract liability balance as of December 31, 2021 and 2020 was immaterial for each period. Revenue recognized during the nine months ended September 30, 2022 and 2021 that was included in the contract liability balance as of December 31, 2021 and 2020 was $ 0.6 million and $ 0.9 million , respectively. Disaggregation of revenue The Company disaggregates revenue from contracts with customers by segment and by the timing of when goods and services are transferred, which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected. The following table provides information regarding revenues disaggregated by segment and the timing of when goods and services are transferred: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Product revenue recognized at a point in time $ 7,616 $ 5,992 $ 22,909 $ 17,565 Product revenue recognized over time 179 194 531 601 Software revenue recognized at a point in time 469 150 1,233 668 Software revenue recognized over time 1,582 1,551 4,753 4,472 Total $ 9,846 $ 7,887 $ 29,426 $ 23,306 No individual customer accounted for more than 10% of sales for the three or nine months ended September 30, 2022 and 2021. Warranty Reserve The Company provides a standard warranty on its GentleWave Systems for a specified period of time. For the three and nine months ended September 30, 2022 and 2021, GentleWave Systems sold were covered by the warranty for a period of up to two years from the date of sale. Estimated warranty costs are recorded as a liability at the time of delivery with a corresponding provision to cost of sales. Warranty expenses expected to be incurred within 12 months from the date of sale are classified as other current liabilities while those expected to be incurred after 12 months from the date of sale are classified as other liabilities in the accompanying unaudited condensed consolidated balance sheets. Warranty accruals are estimated based on the current product costs, the Company’s historical experience, management’s expectations of future conditions and standard maintenance schedules. The Company evaluates this reserve on a regular basis and makes adjustments as necessary. The following table provides a reconciliation of the change in estimated warranty liabilities for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Balance at beginning of period $ 1,730 $ 1,396 $ 1,620 $ 1,584 Provision for warranties issued 328 298 1,108 958 Warranty costs incurred ( 350 ) ( 315 ) ( 1,020 ) ( 1,163 ) Balance at end of period $ 1,708 $ 1,379 $ 1,708 $ 1,379 The warranty liability, current and non-current, are included in other current liabilities and other liabilities, respectively, on the unaudited condensed consolidated balance sheets as follows: September 30, December 31, 2022 2021 (in thousands) Current portion $ 1,212 $ 1,132 Non-current portion 496 488 Total $ 1,708 $ 1,620 Recent Accounti ng Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASU”). ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s unaudited condensed consolidated financial statements. Accounting Pronouncement Recently Adopted In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. The Company adopted ASU 2019-12 in the first quarter of 2022 as an emerging growth company. The adoption did no t have significant impact on the Company's unaudited condensed consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. This will be effective for smaller reporting companies as defined by the SEC for fiscal years beginning aft er December 15, 2023, which for the Company is the first quarter of 2024, with early adoption permitted beginning first quarter of 2021. The Company early adopted the ASU on January 1, 2022 as a smaller reporting company, using the modified retrospective method. The adoption had no impact on the Company's unaudited condensed consolidated financial statements. In May 2021, the FASB issued ASU 2021-04, “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)”, which clarifies and reduces diversity in an issuer’s accounting for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The Company early adopted the ASU on January 1, 2022 . The adoption did no t have significant impact on the Company's unaudited condensed consolidated financial statements. Recent Accounting Updates Not Yet Effective In October 2021, the FASB, issued Accounting Standards Update No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an entity (acquirer) to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, with early adoption permitted. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the impact the standard will have on its condensed consolidated financial statements.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	3. Balance Sheet Components Inventory Inventory consisted of the following: As of September 30, December 31, 2022 2021 (in thousands) Raw materials $ 9,519 $ 4,911 Work in process 440 270 Finished goods 5,226 2,969 Total inventory $ 15,185 $ 8,150 The Company recorded a reserve for excess and obsolete inventory of $ 0.5 million a nd $ 0.7 million at September 30, 2022 and December 31, 2021, respectively. Intangible assets, net Intangible assets as of September 30, 2022 and December 31, 2021 consisted of the following: As of September 30, 2022 Weighted Average Amortization Period Gross Accumulated Net (in years) (in thousands) Developed Technology ( 5 - 10 years) 4.0 $ 2,445 $ 1,034 $ 1,411 Customer relationships ( 7 years) 2.8 1,910 1,080 830 Tradenames ( 10 years) 0.8 360 143 217 Total intangible assets 7.6 $ 4,715 $ 2,257 $ 2,458 As of December 31, 2021 Weighted Average Amortization Period Gross Accumulated Net (in years) (in thousands) Developed Technology ( 5 - 10 years) 4.0 $ 2,445 $ 768 $ 1,677 Customer relationships ( 7 years) 2.8 1,910 875 1,035 Tradenames ( 10 years) 0.8 360 116 244 Total intangible assets 7.6 $ 4,715 $ 1,759 $ 2,956 Amortization expense was $ 0.2 million for each of the three months ended September 30, 2022 and 2021, and was primarily recorded in selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss for such periods. Amortization expense was $ 0.5 million and $ 0.4 million for the nine months ended September 30, 2022 and 2021, respectively, and was primarily recorded in selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss for such periods. The following table presents estimated future annual amortization expense related to intangible assets, net as of September 30, 2022: Future Intangible Asset Amortization Expenses (in thousands) 2022 (remaining three months) $ 166 2023 618 2024 442 2025 386 2026 and thereafter 846 Total future amortization expense $ 2,458

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	4. Fair Value of Financial Instruments The Company’s financial instruments consist principally of cash, cash equivalents, short-term investments, accounts receivable, accounts payable, operating lease liabilities, warrant liabilities, forward obligation, contingent earnout, and a term loan. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 – Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities the Company has the ability to access. Level 2 – Inputs (other than quoted prices included within Level 1) that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3 – Unobservable inputs that are significant to the fair value measurement and reflect the reporting entity’s use of significant management judgment and assumptions when there is little or no market data. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. These include the Black-Scholes option-pricing model which uses inputs such as expected volatility, risk-free interest rate and expected term to determine fair market valuation. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification at each reporting date. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the periods presented. The following table provides the assets and liabilities measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine such value as of September 30, 2022 and December 31, 2021: As of September 30, 2022 Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (in thousands) Assets: Cash equivalents: Money market funds $ 67,478 $ 67,478 $ — $ — Commercial paper 798 — 798 — Total cash equivalents at fair value 68,276 67,478 798 — Short-term investments: U.S. Government agency securities 14,223 14,223 — — Commercial paper and corporate bonds 22,851 — 22,851 — Total short-term investments at fair value 37,074 14,223 22,851 — Total assets at fair value $ 105,350 $ 81,701 $ 23,649 $ — As of December 31, 2021 Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (in thousands) Assets: Money market funds $ 84,102 $ 84,102 $ — $ — Liabilities: Contingent earnout $ 524 $ — $ — $ 524 The following table summarizes the Company's short-term investments, considered available-for-sale, as of September 30, 2022. The Company did no t hold any short-term investments as of December 31, 2021. As of September 30, 2022 Fair Value Cost Basis Unrealized Losses Short-term investments: U.S. Treasury securities $ — $ — $ — U.S. Government agency securities 14,223 14,271 ( 48 ) Commercial paper and corporate bonds 22,851 22,852 ( 1 ) Total short-term investments at fair value $ 37,074 $ 37,123 $ ( 49 ) Recurring liabilities included in Level 3 for the periods presented consisted of a contingent earnout. The following tables present the rollforward of the estimated fair values for instruments classified by the Company within Level 3 of the fair value hierarchy defined above, measured using significant unobservable inputs: Warrant Forward Contingent Total (in thousands) December 31, 2021 $ — $ — $ 524 $ 524 Payment of contingent earnout — — ( 524 ) ( 524 ) September 30, 2022 $ — $ — $ — $ — Warrant Forward Contingent Total (in thousands) December 31, 2020 $ 1,914 $ 2,750 $ 930 $ 5,594 Payment of contingent earnout — — ( 667 ) ( 667 ) Addition 2,135 — — 2,135 Change in fair value 176 550 12 738 September 30, 2021 $ 4,225 $ 3,300 $ 275 $ 7,800 There were no transfers in or out of Level 3 during the nine months ended September 30, 2022 and 2021. Warrants In December 2013, the Company entered into a $ 10.0 million term loan facility with Oxford Finance LLC. The term loan was repaid in full in June 2017 . In connection with the term loan, the Company issued immediately exercisable warrants to the lender for the purchase of 27,397 shares of the Company’s Series C-1 preferred stock equal to three percent of the aggregate amount funded. In June 2017, the Company entered into a term loan facility with Perceptive Credit Holdings, LP, which was subsequently amended (see Note 9). Upon funding of the initial loan, and each initial tranche of the amended loans, the Company issued immediately exercisable warrants to the lender for the purchase of 54,793 shares of the Company’s Series D preferred stock, and 249,313 shares of the Company’s Series E preferred stock. In August 2021, the Company amended its term loan with Perceptive Credit Holdings, LP and Perceptive Credit Holdings III, LP and issued immediately exercisable warrants to Perceptive Credit Holdings III, LP for the purchase of 150,684 shares of the Company’s Series E preferred stock. The fair value at issuance of the Series E preferred stock warrants related to the August 2021 amendment was $ 2.1 million. Prior to the Company's IPO in November 2021, the Company recognized warrants to purchase shares of convertible preferred stock as liabilities, reflecting deemed liquidation provisions of the convertible preferred stock considered contingent redemption provisions that were not solely within the Company's control. Upon the closing of the IPO, the contingent redemption provisions of the warrants were removed with the automatic conversion of the underlying preferred stock to common stock, and the Company revalued the convertible preferred stock warrants and reclassified the liability to stockholders' equity. The common stock warrants are no longer subject to remeasurement subsequent to the IPO. In April 2022, the Company amended its term loan and the warrants previously issued to Perceptive Credit Holdings III, LP and certain of its affiliates to purchase an aggregate of 304,105 shares of its common stock. Such warrants were amended solely to reduce the exercise price of the warrants to $ 12.00 per share. The amendment resulted in revaluation of warrants that was recognized in additional paid-in capital on the unaudited condensed consolidated statement of convertible preferred stock and stockholders’ equity (deficit) as of September 30, 2022. Warrants issued and outstanding at December 31, 2021 included the following: Number of warrants Exercise price per share 27,397 $ 10.95 54,793 $ 17.80 249,313 $ 20.08 331,503 As of September 30, 2021, warrants fully vested and outstanding had estimated fair values ranging from $ 8.13 to $ 14.45 . Fair values were determined using the Black-Scholes option-pricing model with the following input assumptions for the nine months ended September 30, 2021: Nine Months Ended September 30, 2021 Expected volatility range (weighted average) 78.60 % to 84.81 % ( 82.78 %) Dividend yield 0.00 % Risk-free interest rates range (weighted average) 0.34 % to 1.51 % ( 1.35 %) Expected term range (average) 2.25 years to 9.89 years ( 8.25 years) Assumptions were weighted by the relative fair value of the instruments. An increase in the expected volatility, risk-free interest rates, and expected term would result in an increase to the estimated value of the warrants while an increase in the dividend yield would result in a decrease to the estimated value of the warrants. These warrants expire between December 2023 and August 2031 .

Convertible Preferred Stock and

Convertible Preferred Stock and Common Stock	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Convertible Preferred Stock and Common Stock	5. Convertible Preferred Stock and Common Stock Authorized Shares On November 2, 2021, the Company amended and restated its certificate of incorporation and bylaws to provide for, among other things, the Company’s authorized capital stock to consist of 500,000,000 shares of common stock, par value $ 0.001 per share, and 10,000,000 shares of preferred stock, par value $ 0.001 per share. Private Placement and Pre-Funded Warrants On September 27, 2022, the Company completed the Private Placement, issuing an aggregate of 23.0 million shares of its common stock at a purchase price of $ 0.95 per share and pre-funded warrants to purchase an aggregate of 43.3 million shares of common stock at a purchase price of $ 0.949 per pre-funded warrant to certain institutional investors and accredited investors (the "Purchasers"). The pre-funded warrants have an exercise price of $ 0.001 per share of common stock, are immediately exercisable and will remain exercisable until exercised in full. The aggregate net proceeds from the Private Placement, after deducting placement agent fees and other offering expenses, were $ 59.1 million. The pre-funded warrants include a provision whereby the exercisability of the warrants may be limited if, upon exercise, the warrant holder or any of its affiliates would beneficially own more than 9.99 % of the Company's common stock. The threshold is subject to the Purchaser's rights under the pre-funded warrant to increase or decrease such percentage to any other percentage not in excess of 19.99 % upon at least 61 days' prior notice from the Purchaser to the Company. As of September 30, 2022, none of the pre-funded warrants have been exercised. The pre-funded warrants are classified as equity and are accounted for as a component of additional paid-in capital at the time of issuance. The pre-funded warrants are included in the calculation of basic and diluted loss per share. Pursuant to the terms and conditions of the purchase agreements entered into by the Purchasers, the Company is obligated to file a registration statement with the SEC registering the resale by the Purchasers of the shares of common stock issued to them in the Private Placement and the shares of common stock to be issued to them upon exercise of the pre-funded warrants issued to them in the Private Placement within 45 days of the closing of the Private Placement.

Stock-Based Compensation Expens

Stock-Based Compensation Expense	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock Based Compensation Expense	6. Stock-based Compensation Expense Stock-based Compensation Expenses The following tables present the Company's stock-based compensation for equity-settled awards by type ( i.e. , stock options and restricted stock units ("RSUs") granted under the Company's incentive plans, and rights to purchase shares of common stock under the Company's Employee Stock Purchase Plan ("ESPP")) and financial statement lines included in the accompanying unaudited condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Options $ 779 $ 541 $ 2,579 $ 1,448 RSUs 905 — 2,440 — ESPP 39 — 52 — Total stock-based compensation expense $ 1,723 $ 541 $ 5,071 $ 1,448 Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Cost of sales $ 123 $ 50 $ 364 $ 157 Selling, general and administrative 1,435 368 3,820 909 Research and development 165 123 887 382 Total stock-based compensation expense $ 1,723 $ 541 $ 5,071 $ 1,448 C ompensation cost related to unvested stock options and RSUs will be amortized on a straight-line basis over the remaining average service period. The following table presents the unamortized compensation cost and weighted average service period of all unvested outstanding awards as of September 30, 2022: Unamortized Compensation Costs Weighted Average Service Period (in thousands) (years) Options $ 6,126 2.6 RSUs 11,283 3.3 Total unamortized compensation cost $ 17,409 As of September 30, 2022, the total unamortized compensation cost related to the ESPP was not material. Plan Activities T he following table summarizes stock option activity under the Company's incentive plans: Number Weighted Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Options outstanding, December 31, 2021 3,119,993 $ 7.59 Granted 297,516 $ 1.73 Forfeited ( 293,635 ) $ 9.42 Expired ( 67,643 ) $ 6.24 Exercised ( 71,199 ) $ 3.54 $ 142 Options outstanding, September 30, 2022 2,985,032 $ 6.95 6.7 $ — Options vested and exercisable, September 30, 2022 1,719,806 $ 5.68 5.1 $ — Vested and expected to vest after September 30, 2022 2,153,824 $ 6.39 5.7 $ — The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2022 and 2021 was $ 1.16 per share an d $ 8.00 per share, re spectively. The following table summarizes the non-vested stock options as of September 30, 2022 and December 31, 2021: Number of Shares Weighted Non-vested Options, December 31, 2021 1,632,852 $ 7.09 Non-vested Options, September 30, 2022 1,265,226 $ 5.98 The total fair value of shares vested during the nine months ended September 30, 2022 and 2021 was $ 2.6 million and $ 0.4 million , respectively. Certain stock option grants under the 2017 Stock Incentive Plan (the "2017 Plan") allow the recipient to exercise the options prior to the options becoming fully vested. Under the 2017 Plan, the Company retains the right to repurchase shares of its common shares that have been issued upon early exercise of options at the original issue price. During the three and nine months ended September 30, 2022, the Company did not repurchase any shares. There was no material amount of shares of common stock subject to repurchase as of September 30, 2022. Cash received from the early exercise of unvested stock options is initially recorded as a liability and is released to equity over the vesting period. During the nine months ended September 30, 2022 and 2021, the vesting of early exercised stock options were immaterial. T he following table summarizes RSU activity under the Company's incentive plans: Number Weighted RSUs outstanding, December 31, 2021 338,149 $ 9.37 Granted 3,432,279 $ 4.40 Vested ( 303,296 ) $ 6.38 Forfeited ( 531,198 ) $ 5.34 RSUs outstanding, September 30, 2022 2,935,934 $ 4.63

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	7. Leases The Company leases office space under operating leases with expirations ranging from June 2023 to August 2026, some of which include rent escalations or an option to extend the lease for up to three years per renewal. The exercise of lease renewal options is at the sole discretion of the Company. Where real estate leases contain an option to renew, any period beyond the option date is only included as part of the lease term if the Company is reasonably certain to exercise the option. As of September 30, 2022 , the Company has not entered into any leases that have not yet commenced that would entitle the Company to significant rights or create additional obligations. The Company determines whether a contract is or contains a lease at the inception of the contract. A contract will be deemed to be or contain a lease if the contract conveys the right to control and direct the use of identified property, plant, or equipment for a period of time in exchange for consideration. The Company generally must also have the right to obtain substantially all of the economic benefits from the use of the property, plant, and equipment. The Company has elected the practical expedient to not separate its lease component from non-lease component for its real estate leases. The Company has elected the practical expedient not to apply the lease recognition requirements to short-term leases with an initial term of 12 months or less. The Company uses either its incremental borrowing rate or the implicit rate in the lease agreement as the basis to calculate the present value of future lease payments at lease commencement. The incremental borrowing rate represents the rate the Company would have to pay to borrow funds on a collateralized basis over a similar term and in a similar economic environment. Future minimum lease payments under these leases are as follows: Lease Amounts (in thousands) 2022 (remaining three months) $ 312 2023 1,089 2024 681 2025 169 2026 and thereafter 23 Total future minimum lease payments 2,274 Less: Imputed Interest ( 171 ) Present value of operating lease liabilities $ 2,103 Less: Current portion 982 Long-term operating lease liabilities $ 1,121 Weighted average remaining lease term in years 2.26 Weighted average discount rate 7.49 % Variable operating lease expenses consist primarily of real estate taxes and insurance. The components of lease expense and related cash flows were as follows: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Rent expense $ 319 $ 303 $ 956 $ 892 Variable lease costs 26 25 79 72 Total $ 345 $ 328 $ 1,035 $ 964 Cash paid for operating leases $ 321 $ 316 $ 951 $ 894 Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Cost of sales $ 58 $ 55 $ 174 $ 162 Selling, general and administrative 287 273 861 802 Total $ 345 $ 328 $ 1,035 $ 964

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business, including without limitation, actions with respect to intellectual property, employment, regulatory, product liability and contractual matters. In connection with these proceedings or matters, the Company regularly assesses the probability and amount (or range) of possible issues based on the developments in these proceedings or matters. A liability is recorded in the accompanying unaudited condensed consolidated financial statements if it is determined that it is probable that a loss has been incurred, and that the amount (or range) of the loss can be reasonably estimated. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.

Term Loan

Term Loan	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Term Loan	9. Term Loan Perceptive loan On August 23, 2021, the Company entered into a fifth amendment to its Credit Agreement and Guaranty with Perceptive Credit Holdings, LP (the " Perceptive Loan"), which transferred the loan to Perceptive Credit Holdings III, LP ("Perceptive"). In connection with this transfer and assignment, the Company entered into an amended and restated credit agreement and guaranty with Perceptive (the "Amended Perceptive Loan Agreement"), which provides for two additional tranches of delayed-draw term loans of $ 10.0 million each, for an aggregate amount of $ 20.0 million (the "Amended Perceptive Loan"), and extended the maturity date for repayment, including with respect to amounts owed in connection with the existing delayed-draw term loan, to August 23, 2026 . In conjunction with the Amended Perceptive Loan, the Company paid a closing fee equal to $ 0.5 million as well as the lender’s legal fees and expenses. The Company accounted for the amendment as a modification. In connection with the Amended Perceptive Loan Agreement, the Company issued a warrant to purchase 150,685 shares of its Series E convertible preferred stock at a purchase price of $ 20.08 per share to Perceptive. Upon the closing of the Company's IPO, this convertible preferred stock warrant was converted into a warrant to purchase 150,685 shares of its common stock at a purchase price of $ 20.08 per share. On April 6, 2022, the Company entered into Amendment No. 1 (the “Amendment”) to the Amended Perceptive Loan Agreemen t. The Amendment extended the borrowing deadline for the first tranche of $ 10.0 million of delayed-draw term loans from December 31, 2021 to September 3 0, 2022 , subject to the Company having generated at least $ 36.0 million in revenue for the 12 consecutive month period most recently ended prior to the borrowing date. The Amendment also extended the borrowing deadline for the second tranche of $ 10.0 million delayed-draw term loans from March 31, 2022 to June 30, 2023 , subject to (i) the Company having generated at least $ 46.0 million in revenue for the 12 consecutive month period most recently ended prior to the borrowing date; and (ii) the closing market capitalization of the Company being at least $ 100.0 million on each trading day of the period of 15 consecutive trading days ending on the business day the bor rowing notice for the tranche is delivered to Perceptive. The Company borrowed the first tranche of $ 10.0 million on July 29, 2022 and received a net proceeds of $ 9.9 million. As a condition to entering into the Amendment, on April 6, 2022, the Company also amended the warrants previously issued to Perceptive and certain of its affiliates to purchase an aggregate of 304,105 shares of its common stock. Such warrants were amended solely to reduce the exercise price of the warrants to $ 12.00 per share. In August 2022, a portion of these warrants representing 153,421 shares were transferred to a third party and its affiliates. For the nine months ended September 30, 2022 , the effective interest rate of the Amended Perceptive Loan, as amended, was 14.52 %. As of September 30, 2022 and 2021, the fair value of the Amended Perceptive Loan, as amended, approximates its carrying amount. Future principal repayments on the Amended Perceptive Loan, as amended, as of September 30, 2022 , are as follows: Principal (in thousands) 2026 $ 40,000 Total $ 40,000 The Amended Perceptive Loan Agreement, as amended, includes financial covenants that require the Company to (i) maintain, at all times, a minimum aggregate balance of $ 3.0 million in cash in one or more controlled accounts, and (ii) satisfy certain minimum revenue thresholds, measured for the 12 consecutive month period on each calendar quarter-end until June 30, 2026. These thresholds increase over time and range from $ 26.4 million for the twelve-month period ended September 30, 2021 to $ 95.3 million for the twelve month period ended June 30, 2026. Failure to satisfy these financial covenants would constitute an event of default under the agreement. During the nine months ended September 30, 2022 , the Company was in compliance with all financial covenants and conditions required by the outstanding Amended Perceptive Loan Agreement, as amended.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes The Company maintains a full valuation allowance against its net deferred tax assets as of September 30, 2022 based on the current assessment that it is not more likely than not that these future benefits will be realized before expiration. No material income tax expense or benefit has been recorded given the valuation allowance position and projected taxable losses in the jurisdictions where the Company files income tax returns. The Company has not experienced any significant increases or decreases to its unrecognized tax benefits since December 31, 2021 and does not expect any within the next 12 months. The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. Utilization of the net operating loss carryforwards may be subject to substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change,” as defined by Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. The Company has not completed an analysis regarding the limitation of net operating loss and R&D credit carryforwards as of September 30, 2022. The Company is subject to U.S. federal and various states income taxes. The federal returns for tax years 2018 through 2021 remain open to examination and the state returns remain subject to examination for tax years 2017 through 2021 . Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authorities. All other state jurisdictions remain open to examination.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Information	12. Segment Information The Company operates and reports its results in two business segments, Product and Software. The Company reports segment information based on the management approach. The management approach designates the internal reporting used by the Company's Chief Operating Decision Maker ("CODM") for decision making and performance assessment as the basis for determining the Company’s reportable segments. The performance measures of the Company’s reportable segments is primarily income (loss) from operations. Income (loss) from operations for each segment includes all revenues, related cost of net revenues, gross margin and operating expenses directly attributable to the segment. The Company’s Product segment includes sales of the Company's GentleWave System console and related accessories and instruments. The Company’s Software segment includes sales of the Company's traditional software licenses for practice management software to enable an integrated digital office for endodontists as well as Software-as-a-Service subscriptions for the software. The following tables present the Company’s segment information for the three and nine months ended September 30, 2022 and 2021 : Three Months Ended September 30, September 30, 2022 2021 (in thousands, except percentage data) Product Software Total Product Software Total Revenue $ 7,795 $ 2,051 $ 9,846 $ 6,186 $ 1,701 $ 7,887 Cost of sales 6,875 653 7,528 5,260 578 5,838 Gross profit 920 1,398 2,318 926 1,123 2,049 Gross margin 12 % 68 % 24 % 15 % 66 % 26 % Operating expenses: Selling, general and administrative 12,141 445 12,586 7,961 534 8,495 Research and development 3,891 437 4,328 4,214 419 4,633 Change in fair value of contingent earnout — — — 19 — 19 Total operating expenses 16,032 882 16,914 12,194 953 13,147 (Loss) income from operations $ ( 15,112 ) $ 516 $ ( 14,596 ) $ ( 11,268 ) $ 170 $ ( 11,098 ) Nine Months Ended September 30, September 30, 2022 2021 (in thousands, except percentage data) Product Software Total Product Software Total Revenue $ 23,440 $ 5,986 $ 29,426 $ 18,166 $ 5,140 $ 23,306 Cost of sales 20,338 1,938 22,276 15,668 1,754 17,422 Gross profit 3,102 4,048 7,150 2,498 3,386 5,884 Gross margin 13 % 68 % 24 % 14 % 66 % 25 % Operating expenses: Selling, general and administrative 35,911 1,482 37,393 20,893 1,507 22,400 Research and development 11,874 1,322 13,196 13,075 1,235 14,310 Change in fair value of contingent earnout — — — 12 — 12 Total operating expenses 47,785 2,804 50,589 33,980 2,742 36,722 (Loss) income from operations $ ( 44,683 ) $ 1,244 $ ( 43,439 ) $ ( 31,482 ) $ 644 $ ( 30,838 ) Segment Assets: As of September 30, December 31, 2022 2021 (in thousands) Product $ 132,245 $ 104,588 Software 10,695 10,911 Total $ 142,940 $ 115,499

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands, except shares and per share data) Numerator: Net loss attributable to common stock holders $ ( 15,539 ) $ ( 12,733 ) $ ( 46,198 ) $ ( 34,788 ) Denominator: Weighted-average shares outstanding – basic and diluted 33,116,536 1,232,921 28,688,018 1,218,815 Net loss per share – basic and diluted $ ( 0.47 ) $ ( 10.33 ) $ ( 1.61 ) $ ( 28.54 ) The Company computes basic loss per share using the net loss and the weighted average number of common shares outstanding during the period. For both the three and nine months ended September 30, 2022, shares of the Company's common stock underlying the pre-funded warrants sold in the Private Placement are included in the calculation of the basic shares in accordance with ASC 260, Earnings Per Share . The Company incurred a net loss for the periods presented and as a result, all outstanding equity awards and warrants have been excluded from such periods because including them would be anti-dilutive. See outstanding equity awards in Note 6, Stock-based Compensation Expense and warrants in Note 4, Fair Value of Financial Instruments.

Summary Accounting Policies a_2

Summary Accounting Policies and Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make informed estimates, judgements and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and disclosures in the accompanying notes, including estimates of probable losses and expenses, as of the date of the accompanying unaudited condensed consolidated financial statements. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of these unaudited condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including the expected business and operational changes, the sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from the estimates and assumptions used in the preparation of the accompanying unaudited condensed consolidated financial statements under different assumptions or conditions.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include U.S. Treasury bills, deposits, money market funds and commercial paper.
Short-Term Investments	Short-Term Investments Short-term investments consist of available-for-sale U.S. Treasury securities, U.S. government agency securities, corporate bonds and commercial paper with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company’s condensed consolidated statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.
Revenue Recognition	Revenue Recognition Contracts with Customers The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Specifically, the Company applies the following five core principles to recognize revenue: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies a performance obligation. Product revenue is generated from sales of the GentleWave console and related PIs and accessories. Software revenue is generated from sales of The Digital Office ("TDO") endodontist practice management software licenses. The Company’s products are sold primarily in the United States and Canada directly to customers through its field sales force. Performance Obligations The Company’s performance obligations primarily arise from the manufacture and delivery of the GentleWave System, related PIs and accessories, and the delivery or license of TDO software and related ancillary services. Payment terms are typically on open credit terms consistent with industry practice and do not have significant financing components. Consideration may be variable based on volume. The Company considers the individual deliverables in its product offering as separate performance obligations and assesses whether each promised good or service is distinct. The total contract transaction price is determined based on the consideration expected to be received, based on the stated value in contractual arrangements or the estimated cash to be collected in no-contracted arrangements, and is allocated to the identified performance obligations based upon the relative standalone selling prices of the performance obligations. The stand-alone selling price is based on an observable price offered to other comparable customers. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer and market conditions. The Company regularly reviews and updates standalone selling prices as necessary. The consideration the Company receives in exchange for its goods or services is only recognized when it is probable that a significant reversal will not occur. The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration. The Company estimates related variable consideration at the point of sale, including discounts, product returns, refunds, and other similar obligations. Revenue is recognized over time when the customer simultaneously receives and consumes the benefits provided by the Company’s performance. Revenue is recognized at a point in time if the criteria for recognizing revenue over time are not met, and the Company has transferred control of the goods to the customer. Product revenue is recognized at a point in time when the Company has transferred control to the customer, which is generally when title of the goods transfers to the customer. Software is licensed via delivery to the customer or via a service arrangement under which cloud-based access is provided on a subscription basis (software-as-a-service). When a fixed up-front license fee is received in exchange for the delivery of software, revenue is recognized at the point in time when the delivery of the software has occurred. When software is licensed on a subscription basis, revenue is recognized over the respective license period. The Company also sells extended service contracts on its GentleWave Systems. Sales of extended service contracts are recorded as deferred revenue until such time as the standard warranty expires, which is generally up to two years from the date of sale. Service contract revenue is recognized on a straight-line basis over time consistent with the life of the related service contract in proportion to the costs incurred in fulfilling performance obligations under the service contract. Revenue for technical support and other services is recognized ratably over the performance obligation period. The Company generally does not experience returns. If necessary, a provision is recorded for estimated sales returns and allowances and is deducted from gross product revenue to arrive at net product revenue in the period the related revenue is recorded. These estimates are based on historical sales returns and allowances and other known factors. Actual returns and claims in any future period are inherently uncertain and thus may differ from these estimates. If actual or expected future returns and claims are significantly greater or lower than the reserves established, a reduction or increase to revenue will be recorded in the period in which such a determination is made. All non-income government-assessed taxes (sales and use taxes) collected from the Company’s customers and remitted to governmental agencies are recorded in accrued expenses until they are remitted to the government agency. The Company has adopted the practical expedient permitting the direct expensing of costs incurred to obtain contracts where the amortization of such costs would occur over one year or less, and it applied to substantially all the Company’s contracts. Contract liabilities The Company recognizes a contract liability when a customer pays for goods or services for which the Company has not yet transferred control. The balances of the Company’s contract liabilities are as follows: As of September 30, December 31, 2022 2021 (in thousands) Extended service contracts $ 315 $ 251 Subscription software licenses 660 520 Total contract liabilities $ 975 $ 771 Contract liabilities are included within other current liabilities in the accompanying unaudited condensed consolidated balance sheets. Revenue recognized during the three months ended September 30, 2022 and 2021 that was included in the contract liability balance as of December 31, 2021 and 2020 was immaterial for each period. Revenue recognized during the nine months ended September 30, 2022 and 2021 that was included in the contract liability balance as of December 31, 2021 and 2020 was $ 0.6 million and $ 0.9 million , respectively. Disaggregation of revenue The Company disaggregates revenue from contracts with customers by segment and by the timing of when goods and services are transferred, which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected. The following table provides information regarding revenues disaggregated by segment and the timing of when goods and services are transferred: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Product revenue recognized at a point in time $ 7,616 $ 5,992 $ 22,909 $ 17,565 Product revenue recognized over time 179 194 531 601 Software revenue recognized at a point in time 469 150 1,233 668 Software revenue recognized over time 1,582 1,551 4,753 4,472 Total $ 9,846 $ 7,887 $ 29,426 $ 23,306 No individual customer accounted for more than 10% of sales for the three or nine months ended September 30, 2022 and 2021.
Warranty Reserve	Warranty Reserve The Company provides a standard warranty on its GentleWave Systems for a specified period of time. For the three and nine months ended September 30, 2022 and 2021, GentleWave Systems sold were covered by the warranty for a period of up to two years from the date of sale. Estimated warranty costs are recorded as a liability at the time of delivery with a corresponding provision to cost of sales. Warranty expenses expected to be incurred within 12 months from the date of sale are classified as other current liabilities while those expected to be incurred after 12 months from the date of sale are classified as other liabilities in the accompanying unaudited condensed consolidated balance sheets. Warranty accruals are estimated based on the current product costs, the Company’s historical experience, management’s expectations of future conditions and standard maintenance schedules. The Company evaluates this reserve on a regular basis and makes adjustments as necessary. The following table provides a reconciliation of the change in estimated warranty liabilities for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Balance at beginning of period $ 1,730 $ 1,396 $ 1,620 $ 1,584 Provision for warranties issued 328 298 1,108 958 Warranty costs incurred ( 350 ) ( 315 ) ( 1,020 ) ( 1,163 ) Balance at end of period $ 1,708 $ 1,379 $ 1,708 $ 1,379 The warranty liability, current and non-current, are included in other current liabilities and other liabilities, respectively, on the unaudited condensed consolidated balance sheets as follows: September 30, December 31, 2022 2021 (in thousands) Current portion $ 1,212 $ 1,132 Non-current portion 496 488 Total $ 1,708 $ 1,620
Recent Accounting Pronouncements	Recent Accounti ng Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASU”). ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s unaudited condensed consolidated financial statements. Accounting Pronouncement Recently Adopted In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. The Company adopted ASU 2019-12 in the first quarter of 2022 as an emerging growth company. The adoption did no t have significant impact on the Company's unaudited condensed consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. This will be effective for smaller reporting companies as defined by the SEC for fiscal years beginning aft er December 15, 2023, which for the Company is the first quarter of 2024, with early adoption permitted beginning first quarter of 2021. The Company early adopted the ASU on January 1, 2022 as a smaller reporting company, using the modified retrospective method. The adoption had no impact on the Company's unaudited condensed consolidated financial statements. In May 2021, the FASB issued ASU 2021-04, “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)”, which clarifies and reduces diversity in an issuer’s accounting for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The Company early adopted the ASU on January 1, 2022 . The adoption did no t have significant impact on the Company's unaudited condensed consolidated financial statements. Recent Accounting Updates Not Yet Effective In October 2021, the FASB, issued Accounting Standards Update No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an entity (acquirer) to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, with early adoption permitted. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the impact the standard will have on its condensed consolidated financial statements.

Summary of Accounting Policies

Summary of Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Balances of Contract Liabilities	The Company recognizes a contract liability when a customer pays for goods or services for which the Company has not yet transferred control. The balances of the Company’s contract liabilities are as follows: As of September 30, December 31, 2022 2021 (in thousands) Extended service contracts $ 315 $ 251 Subscription software licenses 660 520 Total contract liabilities $ 975 $ 771
Schedule of Revenues Disaggregated by Segment and Timing of Goods and Services Transferred	The following table provides information regarding revenues disaggregated by segment and the timing of when goods and services are transferred: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Product revenue recognized at a point in time $ 7,616 $ 5,992 $ 22,909 $ 17,565 Product revenue recognized over time 179 194 531 601 Software revenue recognized at a point in time 469 150 1,233 668 Software revenue recognized over time 1,582 1,551 4,753 4,472 Total $ 9,846 $ 7,887 $ 29,426 $ 23,306
Schedule of Reconciliation of Change in Estimated Warranty	The following table provides a reconciliation of the change in estimated warranty liabilities for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Balance at beginning of period $ 1,730 $ 1,396 $ 1,620 $ 1,584 Provision for warranties issued 328 298 1,108 958 Warranty costs incurred ( 350 ) ( 315 ) ( 1,020 ) ( 1,163 ) Balance at end of period $ 1,708 $ 1,379 $ 1,708 $ 1,379
Schedule of Warranty Liability Current and Non-Current are Included in Other Current Liabilities and Other Liabilities Respectively on Unaudited Condensed Consolidated Balance Sheets	The warranty liability, current and non-current, are included in other current liabilities and other liabilities, respectively, on the unaudited condensed consolidated balance sheets as follows: September 30, December 31, 2022 2021 (in thousands) Current portion $ 1,212 $ 1,132 Non-current portion 496 488 Total $ 1,708 $ 1,620

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Schedule of Inventory	Inventory Inventory consisted of the following: As of September 30, December 31, 2022 2021 (in thousands) Raw materials $ 9,519 $ 4,911 Work in process 440 270 Finished goods 5,226 2,969 Total inventory $ 15,185 $ 8,150
Schedule of Intangible Assets, Net	Intangible assets as of September 30, 2022 and December 31, 2021 consisted of the following: As of September 30, 2022 Weighted Average Amortization Period Gross Accumulated Net (in years) (in thousands) Developed Technology ( 5 - 10 years) 4.0 $ 2,445 $ 1,034 $ 1,411 Customer relationships ( 7 years) 2.8 1,910 1,080 830 Tradenames ( 10 years) 0.8 360 143 217 Total intangible assets 7.6 $ 4,715 $ 2,257 $ 2,458 As of December 31, 2021 Weighted Average Amortization Period Gross Accumulated Net (in years) (in thousands) Developed Technology ( 5 - 10 years) 4.0 $ 2,445 $ 768 $ 1,677 Customer relationships ( 7 years) 2.8 1,910 875 1,035 Tradenames ( 10 years) 0.8 360 116 244 Total intangible assets 7.6 $ 4,715 $ 1,759 $ 2,956
Schedule of Estimated Future Annual Amortization Expense Related to Intangible Assets	The following table presents estimated future annual amortization expense related to intangible assets, net as of September 30, 2022: Future Intangible Asset Amortization Expenses (in thousands) 2022 (remaining three months) $ 166 2023 618 2024 442 2025 386 2026 and thereafter 846 Total future amortization expense $ 2,458

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table provides the assets and liabilities measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine such value as of September 30, 2022 and December 31, 2021: As of September 30, 2022 Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (in thousands) Assets: Cash equivalents: Money market funds $ 67,478 $ 67,478 $ — $ — Commercial paper 798 — 798 — Total cash equivalents at fair value 68,276 67,478 798 — Short-term investments: U.S. Government agency securities 14,223 14,223 — — Commercial paper and corporate bonds 22,851 — 22,851 — Total short-term investments at fair value 37,074 14,223 22,851 — Total assets at fair value $ 105,350 $ 81,701 $ 23,649 $ — As of December 31, 2021 Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (in thousands) Assets: Money market funds $ 84,102 $ 84,102 $ — $ — Liabilities: Contingent earnout $ 524 $ — $ — $ 524
Schedule of Rollforward of the Estimate Fair Values for Instruments	The following tables present the rollforward of the estimated fair values for instruments classified by the Company within Level 3 of the fair value hierarchy defined above, measured using significant unobservable inputs: Warrant Forward Contingent Total (in thousands) December 31, 2021 $ — $ — $ 524 $ 524 Payment of contingent earnout — — ( 524 ) ( 524 ) September 30, 2022 $ — $ — $ — $ — Warrant Forward Contingent Total (in thousands) December 31, 2020 $ 1,914 $ 2,750 $ 930 $ 5,594 Payment of contingent earnout — — ( 667 ) ( 667 ) Addition 2,135 — — 2,135 Change in fair value 176 550 12 738 September 30, 2021 $ 4,225 $ 3,300 $ 275 $ 7,800
Summary of Short-Term Investments	The following table summarizes the Company's short-term investments, considered available-for-sale, as of September 30, 2022. The Company did no t hold any short-term investments as of December 31, 2021. As of September 30, 2022 Fair Value Cost Basis Unrealized Losses Short-term investments: U.S. Treasury securities $ — $ — $ — U.S. Government agency securities 14,223 14,271 ( 48 ) Commercial paper and corporate bonds 22,851 22,852 ( 1 ) Total short-term investments at fair value $ 37,074 $ 37,123 $ ( 49 )
Summary of Warrants Issued and Outstanding	Warrants issued and outstanding at December 31, 2021 included the following: Number of warrants Exercise price per share 27,397 $ 10.95 54,793 $ 17.80 249,313 $ 20.08 331,503
Summary of Fair Values Determined Using Black-Scholes Option-Pricing Model	As of September 30, 2021, warrants fully vested and outstanding had estimated fair values ranging from $ 8.13 to $ 14.45 . Fair values were determined using the Black-Scholes option-pricing model with the following input assumptions for the nine months ended September 30, 2021: Nine Months Ended September 30, 2021 Expected volatility range (weighted average) 78.60 % to 84.81 % ( 82.78 %) Dividend yield 0.00 % Risk-free interest rates range (weighted average) 0.34 % to 1.51 % ( 1.35 %) Expected term range (average) 2.25 years to 9.89 years ( 8.25 years)

Stock-Based Compensation Expe_2

Stock-Based Compensation Expense (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	Stock-based Compensation Expenses The following tables present the Company's stock-based compensation for equity-settled awards by type ( i.e. , stock options and restricted stock units ("RSUs") granted under the Company's incentive plans, and rights to purchase shares of common stock under the Company's Employee Stock Purchase Plan ("ESPP")) and financial statement lines included in the accompanying unaudited condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Options $ 779 $ 541 $ 2,579 $ 1,448 RSUs 905 — 2,440 — ESPP 39 — 52 — Total stock-based compensation expense $ 1,723 $ 541 $ 5,071 $ 1,448 Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Cost of sales $ 123 $ 50 $ 364 $ 157 Selling, general and administrative 1,435 368 3,820 909 Research and development 165 123 887 382 Total stock-based compensation expense $ 1,723 $ 541 $ 5,071 $ 1,448
Schedule of Unamortized Compensation Cost and Weighted Average Service Period of Unvested Outstanding Awards	C ompensation cost related to unvested stock options and RSUs will be amortized on a straight-line basis over the remaining average service period. The following table presents the unamortized compensation cost and weighted average service period of all unvested outstanding awards as of September 30, 2022: Unamortized Compensation Costs Weighted Average Service Period (in thousands) (years) Options $ 6,126 2.6 RSUs 11,283 3.3 Total unamortized compensation cost $ 17,409
Summary of Stock Option Activity under Incentive Plans	T he following table summarizes stock option activity under the Company's incentive plans: Number Weighted Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Options outstanding, December 31, 2021 3,119,993 $ 7.59 Granted 297,516 $ 1.73 Forfeited ( 293,635 ) $ 9.42 Expired ( 67,643 ) $ 6.24 Exercised ( 71,199 ) $ 3.54 $ 142 Options outstanding, September 30, 2022 2,985,032 $ 6.95 6.7 $ — Options vested and exercisable, September 30, 2022 1,719,806 $ 5.68 5.1 $ — Vested and expected to vest after September 30, 2022 2,153,824 $ 6.39 5.7 $ —
Summary of Non Vested Stock Options	The following table summarizes the non-vested stock options as of September 30, 2022 and December 31, 2021: Number of Shares Weighted Non-vested Options, December 31, 2021 1,632,852 $ 7.09 Non-vested Options, September 30, 2022 1,265,226 $ 5.98
Summary of RSU Activity under Incentive Plans	T he following table summarizes RSU activity under the Company's incentive plans: Number Weighted RSUs outstanding, December 31, 2021 338,149 $ 9.37 Granted 3,432,279 $ 4.40 Vested ( 303,296 ) $ 6.38 Forfeited ( 531,198 ) $ 5.34 RSUs outstanding, September 30, 2022 2,935,934 $ 4.63

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Summary of Future Minimum Lease Payments	Future minimum lease payments under these leases are as follows: Lease Amounts (in thousands) 2022 (remaining three months) $ 312 2023 1,089 2024 681 2025 169 2026 and thereafter 23 Total future minimum lease payments 2,274 Less: Imputed Interest ( 171 ) Present value of operating lease liabilities $ 2,103 Less: Current portion 982 Long-term operating lease liabilities $ 1,121 Weighted average remaining lease term in years 2.26 Weighted average discount rate 7.49 %
Components of Lease Expense and Related Cash Flows	Variable operating lease expenses consist primarily of real estate taxes and insurance. The components of lease expense and related cash flows were as follows: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Rent expense $ 319 $ 303 $ 956 $ 892 Variable lease costs 26 25 79 72 Total $ 345 $ 328 $ 1,035 $ 964 Cash paid for operating leases $ 321 $ 316 $ 951 $ 894 Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands) Cost of sales $ 58 $ 55 $ 174 $ 162 Selling, general and administrative 287 273 861 802 Total $ 345 $ 328 $ 1,035 $ 964

Term Loan (Tables)

Term Loan (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Future Principal Repayments of Term Loan	Future principal repayments on the Amended Perceptive Loan, as amended, as of September 30, 2022 , are as follows: Principal (in thousands) 2026 $ 40,000 Total $ 40,000

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Summary of Segment Information	The following tables present the Company’s segment information for the three and nine months ended September 30, 2022 and 2021 : Three Months Ended September 30, September 30, 2022 2021 (in thousands, except percentage data) Product Software Total Product Software Total Revenue $ 7,795 $ 2,051 $ 9,846 $ 6,186 $ 1,701 $ 7,887 Cost of sales 6,875 653 7,528 5,260 578 5,838 Gross profit 920 1,398 2,318 926 1,123 2,049 Gross margin 12 % 68 % 24 % 15 % 66 % 26 % Operating expenses: Selling, general and administrative 12,141 445 12,586 7,961 534 8,495 Research and development 3,891 437 4,328 4,214 419 4,633 Change in fair value of contingent earnout — — — 19 — 19 Total operating expenses 16,032 882 16,914 12,194 953 13,147 (Loss) income from operations $ ( 15,112 ) $ 516 $ ( 14,596 ) $ ( 11,268 ) $ 170 $ ( 11,098 ) Nine Months Ended September 30, September 30, 2022 2021 (in thousands, except percentage data) Product Software Total Product Software Total Revenue $ 23,440 $ 5,986 $ 29,426 $ 18,166 $ 5,140 $ 23,306 Cost of sales 20,338 1,938 22,276 15,668 1,754 17,422 Gross profit 3,102 4,048 7,150 2,498 3,386 5,884 Gross margin 13 % 68 % 24 % 14 % 66 % 25 % Operating expenses: Selling, general and administrative 35,911 1,482 37,393 20,893 1,507 22,400 Research and development 11,874 1,322 13,196 13,075 1,235 14,310 Change in fair value of contingent earnout — — — 12 — 12 Total operating expenses 47,785 2,804 50,589 33,980 2,742 36,722 (Loss) income from operations $ ( 44,683 ) $ 1,244 $ ( 43,439 ) $ ( 31,482 ) $ 644 $ ( 30,838 )
Segment Assets	Segment Assets: As of September 30, December 31, 2022 2021 (in thousands) Product $ 132,245 $ 104,588 Software 10,695 10,911 Total $ 142,940 $ 115,499

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 (in thousands, except shares and per share data) Numerator: Net loss attributable to common stock holders $ ( 15,539 ) $ ( 12,733 ) $ ( 46,198 ) $ ( 34,788 ) Denominator: Weighted-average shares outstanding – basic and diluted 33,116,536 1,232,921 28,688,018 1,218,815 Net loss per share – basic and diluted $ ( 0.47 ) $ ( 10.33 ) $ ( 1.61 ) $ ( 28.54 ) The Company computes basic loss per share using the net loss and the weighted average number of common shares outstanding during the period. For both the three and nine months ended September 30, 2022, shares of the Company's common stock underlying the pre-funded warrants sold in the Private Placement are included in the calculation of the basic shares in accordance with ASC 260, Earnings Per Share .

Organization and Basis of Pre_2

Organization and Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands				3 Months Ended						9 Months Ended
	Sep. 27, 2022 USD ($) $ / shares shares	Nov. 02, 2021 USD ($) $ / shares shares	Oct. 20, 2021	Sep. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2022 USD ($) Segment $ / shares shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares
Organization And Basis Of Presentation [Line Items]
Reverse stock split										On October 20, 2021, the Company’s Board of Directors (the "Board") approved an amendment to the Company’s certificate of incorporation to effect a reverse split of shares of the Company’s common stock and convertible preferred stock on a 1-for-1.825 basis (the “Reverse Stock Split”). The par values of the common stock and convertible preferred stock were not adjusted as a result of the Reverse Stock Split.
Stock split, Conversion ratio			0.5479
Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses | $										$ 20,623
Common stock, shares authorized		500,000,000		500,000,000						500,000,000		500,000,000
Common stock, par value | $ / shares		$ 0.001		$ 0.001						$ 0.001		$ 0.001
Preferred stock, shares authorized		10,000,000		10,000,000						10,000,000		10,000,000
Preferred stock, par value | $ / shares		$ 0.001		$ 0.001						$ 0.001		$ 0.001
Cash and cash equivalents | $				$ 68,512						$ 68,512		$ 84,641
Short-term investments | $				37,074						37,074
Accumulated deficit | $				(358,242)						(358,242)		$ (312,044)
Net loss | $				$ 15,539	$ 15,137	$ 15,522	$ 12,733	$ 11,149	$ 10,906	46,198	$ 34,788
Cash and cash equivalents used in operations | $										$ 46,826	$ 33,880
Operating and Reportable segments | Segment										2
Common stock, shares issued				49,803,355						49,803,355		26,383,225
Common Stock
Organization And Basis Of Presentation [Line Items]
Common stock shares issued				23,045,536
Warrants
Organization And Basis Of Presentation [Line Items]
Conversion of convertible preferred stock into number of common stock		331,503
Forward Obligation
Organization And Basis Of Presentation [Line Items]
Common stock, shares issued		224,842
IPO
Organization And Basis Of Presentation [Line Items]
Common stock shares issued		7,800,000
Public offering price per share | $ / shares		$ 12
Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses | $		$ 83,800
IPO | Common Stock
Organization And Basis Of Presentation [Line Items]
Conversion of convertible preferred stock into number of common stock		17,031,887
Private Placement
Organization And Basis Of Presentation [Line Items]
Common stock shares issued	23,000,000
Public offering price per share | $ / shares	$ 0.95
Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses | $	$ 59,100
Prefunded Warrants
Organization And Basis Of Presentation [Line Items]
Common stock shares issued	43,300,000
Public offering price per share | $ / shares	$ 0.949
Warrant exercise price per share | $ / shares	$ 0.001

Summary Accounting Policies a_3

Summary Accounting Policies and Recent Accounting Pronouncements - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) Customer	Sep. 30, 2021 Customer	Sep. 30, 2022 USD ($) Customer	Sep. 30, 2021 USD ($) Customer	Dec. 31, 2021 USD ($)
Summary Of Accounting Policies [Line Items]
Goodwill	$ 8,454		$ 8,454		$ 8,454
Revenue, practical expedient, incremental cost of obtaining contract [true false]			true
Revenue recognized			$ 600	$ 900
ASU 2019-12
Summary Of Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true		true
Change in accounting principle, accounting standards update, immaterial effect [true false]	true		true
ASU 2020-06
Summary Of Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true		true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022		Jan. 01, 2022
ASU 2021-04
Summary Of Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true		true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022		Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect [true false]	true		true
Customer Concentration Risk | Sales
Summary Of Accounting Policies [Line Items]
Number of customer accounted for sales | Customer	0	0	0	0
GentleWave Systems | Maximum
Summary Of Accounting Policies [Line Items]
Standard product warranty period			2 years	2 years

Summary Accounting Policies a_4

Summary Accounting Policies and Recent Accounting Pronouncements- Summary of Balances of Contract Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Summary Of Accounting Policies [Line Items]
Total contract liabilities	$ 975	$ 771
Extended Service Contracts
Summary Of Accounting Policies [Line Items]
Total contract liabilities	315	251
Subscription Software Licenses
Summary Of Accounting Policies [Line Items]
Total contract liabilities	$ 660	$ 520

Summary Accounting Policies a_5

Summary Accounting Policies and Recent Accounting Pronouncements - Schedule of Revenues Disaggregated by Segment and Timing of Goods and Services Transferred (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Summary Of Accounting Policies [Line Items]
Total revenue	$ 9,846	$ 7,887	$ 29,426	$ 23,306
Product
Summary Of Accounting Policies [Line Items]
Total revenue	7,795	6,186	23,440	18,166
Product | Point in Time
Summary Of Accounting Policies [Line Items]
Total revenue	7,616	5,992	22,909	17,565
Product | Over Time
Summary Of Accounting Policies [Line Items]
Total revenue	179	194	531	601
Software
Summary Of Accounting Policies [Line Items]
Total revenue	2,051	1,701	5,986	5,140
Software | Point in Time
Summary Of Accounting Policies [Line Items]
Total revenue	469	150	1,233	668
Software | Over Time
Summary Of Accounting Policies [Line Items]
Total revenue	$ 1,582	$ 1,551	$ 4,753	$ 4,472

Summary Accounting Policies a_6

Summary Accounting Policies and Recent Accounting Pronouncements - Schedule of Reconciliation of Change in Estimated Warranty (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Balance at beginning of period	$ 1,730	$ 1,396	$ 1,620	$ 1,584
Provision for warranties issued	328	298	1,108	958
Warranty costs incurred	(350)	(315)	(1,020)	(1,163)
Balance at end of period	$ 1,708	$ 1,379	$ 1,708	$ 1,379

Summary Accounting Policies a_7

Summary Accounting Policies and Recent Accounting Pronouncements - Schedule of Warranty Liability Current and Non-Current are Included in Other Current Liabilities and Other Liabilities Respectively on Unaudited Condensed Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Current portion	$ 1,212		$ 1,132
Non-current portion	496		488
Total	$ 1,708	$ 1,730	$ 1,620	$ 1,379	$ 1,396	$ 1,584

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 9,519	$ 4,911
Work in process	440	270
Finished goods	5,226	2,969
Total	$ 15,185	$ 8,150

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Reserve for excess and obsolete inventory	$ 500		$ 500		$ 700
Amortization intangible assets			498	$ 420
Selling, General and Administrative
Amortization intangible assets	$ 200	$ 200	$ 500	$ 400

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Intangible Assets Net (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Weighted Average Amortization Period	7 years 7 months 6 days	7 years 7 months 6 days
Gross	$ 4,715	$ 4,715
Accumulated Amortization	2,257	1,759
Net	$ 2,458	$ 2,956
Developed Technology
Finite Lived Intangible Assets [Line Items]
Weighted Average Amortization Period	4 years	4 years
Gross	$ 2,445	$ 2,445
Accumulated Amortization	1,034	768
Net	$ 1,411	$ 1,677
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Weighted Average Amortization Period	2 years 9 months 18 days	2 years 9 months 18 days
Gross	$ 1,910	$ 1,910
Accumulated Amortization	1,080	875
Net	$ 830	$ 1,035
Tradenames
Finite Lived Intangible Assets [Line Items]
Weighted Average Amortization Period	9 months 18 days	9 months 18 days
Gross	$ 360	$ 360
Accumulated Amortization	143	116
Net	$ 217	$ 244

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Intangible Assets Net (Parenthetical) (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Developed Technology | Minimum
Finite Lived Intangible Assets [Line Items]
Estimated useful life	5 years	5 years
Developed Technology | Maximum
Finite Lived Intangible Assets [Line Items]
Estimated useful life	10 years	10 years
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Estimated useful life	7 years	7 years
Tradenames
Finite Lived Intangible Assets [Line Items]
Estimated useful life	10 years	10 years

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Estimated Future Annual Amortization Expense Related to Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
2022 (remaining six months)	$ 166
2023	618
2024	442
2025	386
2026 and thereafter	846
Net	$ 2,458	$ 2,956

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Assets:
Total short-term investments at fair value		$ 0
Total assets at fair value	$ 37,074,000
U.S. Government Agency Securities
Assets:
Total assets at fair value	14,223,000
Commercial Paper and Corporate Bonds
Assets:
Total assets at fair value	22,851,000
Fair Value Measurements Recurring Basis
Assets:
Total cash equivalents at fair value	68,276,000
Total assets at fair value	105,350,000
Fair Value Measurements Recurring Basis | Short-Term Investments
Assets:
Total assets at fair value	37,074,000
Fair Value Measurements Recurring Basis | Contingent Earnout
Liabilities:
Liabilities		524,000
Fair Value Measurements Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total cash equivalents at fair value	67,478,000
Total assets at fair value	81,701,000
Fair Value Measurements Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-Term Investments
Assets:
Total assets at fair value	14,223,000
Fair Value Measurements Recurring Basis | Significant Other Observable Inputs (Level 2)
Assets:
Total cash equivalents at fair value	798,000
Total assets at fair value	23,649,000
Fair Value Measurements Recurring Basis | Significant Other Observable Inputs (Level 2) | Short-Term Investments
Assets:
Total assets at fair value	22,851,000
Fair Value Measurements Recurring Basis | Significant Unobservable Inputs (Level 3) | Contingent Earnout
Liabilities:
Liabilities		524,000
Fair Value Measurements Recurring Basis | Money Market Funds
Assets:
Total cash equivalents at fair value	67,478,000
Total assets at fair value		84,102,000
Fair Value Measurements Recurring Basis | Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total cash equivalents at fair value	67,478,000
Total assets at fair value		$ 84,102,000
Fair Value Measurements Recurring Basis | Commercial Paper
Assets:
Total cash equivalents at fair value	798,000
Fair Value Measurements Recurring Basis | Commercial Paper | Significant Other Observable Inputs (Level 2)
Assets:
Total cash equivalents at fair value	798,000
Fair Value Measurements Recurring Basis | U.S. Government Agency Securities | Short-Term Investments
Assets:
Total assets at fair value	14,223,000
Fair Value Measurements Recurring Basis | U.S. Government Agency Securities | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-Term Investments
Assets:
Total assets at fair value	14,223,000
Fair Value Measurements Recurring Basis | Commercial Paper and Corporate Bonds | Short-Term Investments
Assets:
Total assets at fair value	22,851,000
Fair Value Measurements Recurring Basis | Commercial Paper and Corporate Bonds | Significant Other Observable Inputs (Level 2) | Short-Term Investments
Assets:
Total assets at fair value	$ 22,851,000

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Rollforward of the Estimate Fair Values for Instruments (Details) - Fair Value Measurements Recurring Basis - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 524	$ 5,594
Payment of contingent earnout	(524)	(667)
Addition		2,135
Change in fair value		738
Ending Balance		7,800
Warrant Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance		1,914
Addition		2,135
Change in fair value		176
Ending Balance		4,225
Forward Obligation
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance		2,750
Change in fair value		550
Ending Balance		3,300
Contingent Earnout
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	524	930
Payment of contingent earnout	$ (524)	(667)
Change in fair value		12
Ending Balance		$ 275

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Short-Term Investments (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Short-Term Investments [Abstract]
Fair Value	$ 37,074
Cost Basis	37,123
Unrealized Losses Recognized in AOCI	(49)
US Government Agencies Debt Securities [Member]
Short-Term Investments [Abstract]
Fair Value	14,223
Cost Basis	14,271
Unrealized Losses Recognized in AOCI	(48)
Commercial Paper and Corporate Bonds [Member]
Short-Term Investments [Abstract]
Fair Value	22,851
Cost Basis	22,852
Unrealized Losses Recognized in AOCI	$ (1)

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Additional Information (Details)	1 Months Ended			9 Months Ended
	Aug. 31, 2021 USD ($) shares	Jun. 30, 2017 shares	Dec. 31, 2013 USD ($) shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Apr. 30, 2022 $ / shares shares	Dec. 31, 2021 USD ($) shares
Fair Value Option Quantitative Disclosures [Line Items]
Fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 | $				$ 0	$ 0
Fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 | $				$ 0	$ 0
Warrants issued to purchase preferred stock							331,503
Total short-term investments at fair value | $							$ 0
Minimum
Fair Value Option Quantitative Disclosures [Line Items]
Warrants expiration date				2023-12
Maximum
Fair Value Option Quantitative Disclosures [Line Items]
Warrants expiration date				2031-08
Fair Values | Minimum
Fair Value Option Quantitative Disclosures [Line Items]
Warrants and Rights Outstanding, Measurement Input					8.13
Fair Values | Maximum
Fair Value Option Quantitative Disclosures [Line Items]
Warrants and Rights Outstanding, Measurement Input					14.45
Term Loan | Oxford Finance LLC
Fair Value Option Quantitative Disclosures [Line Items]
Term loan facility amount | $			$ 10,000,000
Debt repayment month and year			2017-06
Percentage of aggregate amount funded to purchase preferred stock			3%
Term Loan | Oxford Finance LLC | Series C-1
Fair Value Option Quantitative Disclosures [Line Items]
Warrants issued to purchase preferred stock			27,397
Term Loan | Perceptive Credit Holdings L P | Series E
Fair Value Option Quantitative Disclosures [Line Items]
Warrants issued to purchase preferred stock		249,313
Term Loan | Perceptive Credit Holdings L P | Series D
Fair Value Option Quantitative Disclosures [Line Items]
Warrants issued to purchase preferred stock		54,793
Term Loan | Perceptive Credit Holdings L P and Perceptive Credit Holdings III L P | Series E
Fair Value Option Quantitative Disclosures [Line Items]
Warrants issued to purchase preferred stock	150,684
Fair value of warrants | $	$ 2,100,000
Term Loan | Perceptive Credit Holdings III, LP
Fair Value Option Quantitative Disclosures [Line Items]
Warrant exercise price per share | $ / shares						$ 12
Term Loan | Perceptive Credit Holdings III, LP | Common Stock
Fair Value Option Quantitative Disclosures [Line Items]
Warrants issued to purchase preferred stock						304,105

Fair Value of Financial Instr_7

Fair Value of Financial Instruments - Summary of Warrants Issued and Outstanding (Details)	Dec. 31, 2021 $ / shares shares
Class Of Warrant Or Right [Line Items]
Number of warrants issued	331,503
Number of warrants outstanding	331,503
Series C-1
Class Of Warrant Or Right [Line Items]
Number of warrants issued	54,793
Number of warrants outstanding	27,397
Exercise Price Per Share | $ / shares	$ 10.95
Series D
Class Of Warrant Or Right [Line Items]
Number of warrants issued	27,397
Number of warrants outstanding	54,793
Exercise Price Per Share | $ / shares	$ 17.80
Series E
Class Of Warrant Or Right [Line Items]
Number of warrants issued	249,313
Number of warrants outstanding	249,313
Exercise Price Per Share | $ / shares	$ 20.08

Fair Value of Financial Instr_8

Fair Value of Financial Instruments - Summary of Fair Values Determined Using Black-Scholes Option-Pricing Model (Details)	Sep. 30, 2021
Expected Volatility | Minimum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants and Rights Outstanding, Measurement Input	78.60
Expected Volatility | Maximum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants and Rights Outstanding, Measurement Input	84.81
Expected Volatility | Weighted Average
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants and Rights Outstanding, Measurement Input	82.78
Dividend Yield
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants and Rights Outstanding, Measurement Input	0
Risk-Free Interest Rates | Minimum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.34
Risk-Free Interest Rates | Maximum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants and Rights Outstanding, Measurement Input	1.51
Risk-Free Interest Rates | Weighted Average
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants and Rights Outstanding, Measurement Input	1.35
Expected Term | Minimum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants and rights outstanding, term	2 years 3 months
Expected Term | Maximum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants and rights outstanding, term	9 years 10 months 20 days
Expected Term | Weighted Average
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants and rights outstanding, term	8 years 3 months

Convertible Preferred Stock a_2

Convertible Preferred Stock and Common Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	Sep. 27, 2022	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Nov. 02, 2021
Class Of Stock [Line Items]
Common stock, par value		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized		500,000,000	500,000,000	500,000,000	500,000,000
Preferred stock, shares authorized		10,000,000	10,000,000	10,000,000	10,000,000
Preferred stock, par value		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Proceeds from issuance of common stock, net of issuance costs			$ 20,623
Private Placement
Class Of Stock [Line Items]
Common stock shares issued	23,000,000
Price per share	$ 0.95
Proceeds from issuance of common stock, net of issuance costs	$ 59,100
Prefunded Warrants
Class Of Stock [Line Items]
Common stock shares issued	43,300,000
Price per share	$ 0.949
Warrant exercise price per share	$ 0.001
Percentage of exercisability of warrants			9.99%
Threshold percentage of warrants			19.99%
Common Stock
Class Of Stock [Line Items]
Common stock shares issued		23,045,536

Stock-Based Compensation Expe_3

Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,723	$ 541	$ 5,071	$ 1,448
Cost of Sales
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	123	50	364	157
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	1,435	368	3,820	909
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	165	123	887	382
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	779	$ 541	2,579	$ 1,448
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	905		2,440
ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 39		$ 52

Stock-Based Compensation Expe_4

Stock-Based Compensation Expense - Schedule of Unamortized Compensation Cost and Weighted Average Service Period of Unvested Outstanding Awards (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized Compensation Costs	$ 17,409
Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized Compensation Costs	$ 6,126
Weighted Average Service Period	2 years 7 months 6 days
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized Compensation Costs	$ 11,283
Weighted Average Service Period	3 years 3 months 18 days

Stock-Based Compensation Expe_5

Stock-Based Compensation Expense - Summary of Stock Option Activities (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of Shares, Options Outstanding, Beginning Balance | shares	3,119,993
Number of Shares, Granted | shares	297,516
Number of Shares, Forfeited | shares	(293,635)
Number of Shares, Exercised | shares	(71,199)
Number of Shares, Expired | shares	(67,643)
Number of Shares, Options Outstanding, Ending Balance | shares	2,985,032
Number of Options Vested and exercisable at September 30, 2022 | shares	1,719,806
Number of Shares, Vested and expected to vest after September 30, 2022 | shares	2,153,824
Weighted Average Exercise Price Per Share, Options Outstanding, Beginning Balance | $ / shares	$ 7.59
Weighted Average Exercise Price Per Share, Granted | $ / shares	1.73
Weighted Average Exercise Price Per Share, Forfeited | $ / shares	9.42
Weighted Average Exercise Price Per Share, Exercised | $ / shares	3.54
Weighted Average Exercise Price Per Share, Expired | $ / shares	6.24
Weighted Average Exercise Price Per Share, Ending Balance | $ / shares	6.95
Weighted Average Exercise Price Per Share, Options Vested and exercisable, September 30, 2022 | $ / shares	5.68
Weighted Average Exercise Price Per Share, Vested and expected to vest after September 30, 2022 | $ / shares	$ 6.39
Weighted- Average Remaining Contractual Life (Years) Outstanding at September 30, 2022	6 years 8 months 12 days
Weighted-Average Remaining Contractual Life (in years) Options Vested and exercisable, September 30, 2022	5 years 1 month 6 days
Weighted-Average Remaining Contractual Life (in years) Vested and expected to vest after September 30, 2022	5 years 8 months 12 days
Aggregate Intrinsic Value, Exercised | $	$ 142

Stock-Based Compensation Expe_6

Stock-Based Compensation Expense - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Weighted-average grant-date fair value of options granted	$ 1.16	$ 8
Fair value of shares vested	$ 2.6	$ 0.4

Stock-Based Compensation Expe_7

Stock-Based Compensation Expense - Summary of Non Vested Options (Details) - Options - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Non-vested Options, December 31, 2021	1,265,226	1,632,852
Number of Shares, Non-vested Options, September 30, 2022	1,265,226	1,632,852
Weighted Average Grant Date Fair Value, Non-vested Options, December 31, 2021	$ 5.98	$ 7.09
Weighted Average Grant Date Fair Value, Non-vested Options, September 30, 2022	$ 5.98	$ 7.09

Stock-based Compensation Expe_8

Stock-based Compensation Expense - Summary of RSU Activity under Incentive Plans (Details) - RSUs	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, RSUs outstanding, Beginning Balance | shares	338,149
Number of Shares, Granted | shares	3,432,279
Number of Shares, Exercised | shares	(303,296)
Number of Shares, Forfeited | shares	(531,198)
Number of Shares, RSUs outstanding, Ending Balance | shares	2,935,934
Weighted Average Grant Date Fair Value, RSUs outstanding, Beginning Balance | $ / shares	$ 9.37
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 4.40
Weighted Average Exercise Date Fair Value, Exercised | $ / shares	6.38
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	$ 5.34
Weighted Average Grant Date Fair Value, RSUs outstanding, Ending Balance | $ / shares	$ 4.63

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease description			The Company leases office space under operating leases with expirations ranging from June 2023 to August 2026, some of which include rent escalations or an option to extend the lease for up to three years per renewal.
Operating lease renewal term	3 years		3 years
Lessee, Operating Lease, Existence of Option to Extend [true false]			true
Operating lease, not yet commenced, description			the Company has not entered into any leases that have not yet commenced that would entitle the Company to significant rights or create additional obligations.
Cash paid for amounts included in the lease liability	$ 321	$ 316	$ 951	$ 894

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
2022 (remaining three months)	$ 312
2023	1,089
2024	681
2025	169
2026 and thereafter	23
Total future minimum lease payments	2,274
Less: Imputed Interest	(171)
Present value of operating lease liabilities	2,103
Less: Current portion	982	$ 975
Long-term operating lease liabilities	$ 1,121	$ 1,730
Weighted average remaining lease term in years	2 years 3 months 3 days
Weighted average discount rate	7.49%

Leases - Components of Lease Ex

Leases - Components of Lease Expense and Related Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Lessee, Lease, Description [Line Items]
Rent expense	$ 319	$ 303	$ 956	$ 892
Variable lease costs	26	25	79	72
Lease costs	345	328	1,035	964
Cost of Sales
Lessee, Lease, Description [Line Items]
Lease costs	58	55	174	162
Selling, General and Administrative
Lessee, Lease, Description [Line Items]
Lease costs	$ 287	$ 273	$ 861	$ 802

Term Loan - Additional Informat

Term Loan - Additional Information (Details) $ / shares in Units, $ in Thousands					1 Months Ended	9 Months Ended	12 Months Ended
	Jul. 29, 2022 USD ($)	Apr. 06, 2022 USD ($) Days $ / shares shares	Nov. 02, 2021 $ / shares shares	Aug. 23, 2021 USD ($) $ / shares shares	Aug. 31, 2022 shares	Sep. 30, 2022 USD ($)	Jun. 30, 2026 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) shares
Debt Instrument [Line Items]
Term loan						$ 36,599			$ 26,496
Net proceeds from debt						9,850
Number of warrants issued | shares									331,503
Amended Perceptive Loan Agreement
Debt Instrument [Line Items]
Aggregate minimum cash balance						$ 3,000
Debt instrument covenant description						The Amended Perceptive Loan Agreement, as amended, includes financial covenants that require the Company to (i) maintain, at all times, a minimum aggregate balance of $3.0 million in cash in one or more controlled accounts, and (ii) satisfy certain minimum revenue thresholds, measured for the 12 consecutive month period on each calendar quarter-end until June 30, 2026. These thresholds increase over time and range from $26.4 million for the twelve-month period ended September 30, 2021 to $95.3 million for the twelve month period ended June 30, 2026. Failure to satisfy these financial covenants would constitute an event of default under the agreement. During the nine months ended September 30, 2022, the Company was in compliance with all financial covenants and conditions required by the outstanding Amended Perceptive Loan Agreement, as amended.
Amendment
Debt Instrument [Line Items]
Number of warrants issued | shares		304,105
Purchase price per share of warrant | $ / shares		$ 12
Maximum market capitalization on each trading day		$ 100,000
Number of consecutive trading days | Days		15
Portion of warrants transferred to third party | shares					153,421
Minimum | Amended Perceptive Loan Agreement
Debt Instrument [Line Items]
Revenue thresholds increase over time								$ 26,400
Maximum | Amended Perceptive Loan Agreement | Forecast
Debt Instrument [Line Items]
Revenue thresholds increase over time							$ 95,300
Tranche One | Amended Perceptive Loan Agreement
Debt Instrument [Line Items]
Borrowed amount	$ 10,000
Net proceeds from debt	$ 9,900
Tranche One | Amendment
Debt Instrument [Line Items]
Delayed draw term loan		$ 10,000
Delayed-draw term loans start date		Dec. 31, 2021
Delayed-draw term loans end date		Sep. 30, 2022
Maximum revenue in borrowing date		$ 36,000
Tranche Two | Amendment
Debt Instrument [Line Items]
Delayed draw term loan		$ 10,000
Delayed-draw term loans start date		Mar. 31, 2022
Delayed-draw term loans end date		Jun. 30, 2023
Maximum revenue in borrowing date		$ 46,000
Perceptive Credit Holdings III, LP
Debt Instrument [Line Items]
Aggregate delayed draw term loan				$ 20,000
Maturity date				Aug. 23, 2026
Term loan, closing fee				$ 500
Effective interest rate percentage						14.52%
Perceptive Credit Holdings III, LP | IPO | Common Stock
Debt Instrument [Line Items]
Number of warrants converted to common stock | shares			150,685
Purchase price per share of common stock | $ / shares			$ 20.08
Perceptive Credit Holdings III, LP | Tranche Two
Debt Instrument [Line Items]
Delayed draw term loan				$ 10,000
Perceptive Credit Holdings III, LP | Tranche Two | Series E Preferred Shares
Debt Instrument [Line Items]
Number of warrants issued | shares				150,685
Purchase price per share of warrant | $ / shares				$ 20.08

Term Loan - Schedule of Future

Term Loan - Schedule of Future Principal Repayments of Term Loan (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Debt Disclosure [Abstract]
2026	$ 40,000
Total	$ 40,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022
Federal
Income Tax Contingency [Line Items]
Open Tax Year	2018 2019 2020 2021
State
Income Tax Contingency [Line Items]
Open Tax Year	2017 2018 2019 2020 2021

Segment Information - Summary o

Segment Information - Summary of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Revenue	$ 9,846	$ 7,887	$ 29,426	$ 23,306
Cost of sales	7,528	5,838	22,276	17,422
Gross profit	$ 2,318	$ 2,049	$ 7,150	$ 5,884
Gross margin	24%	26%	24%	25%
Operating expenses
Selling, general and administrative	$ 12,586	$ 8,495	$ 37,393	$ 22,400
Research and development	4,328	4,633	13,196	14,310
Change in fair value of contingent earnout		19		12
Total operating expenses	16,914	13,147	50,589	36,722
Loss from operations	(14,596)	(11,098)	(43,439)	(30,838)
Product
Segment Reporting Information [Line Items]
Revenue	7,795	6,186	23,440	18,166
Cost of sales	6,875	5,260	20,338	15,668
Gross profit	$ 920	$ 926	$ 3,102	$ 2,498
Gross margin	12%	15%	13%	14%
Operating expenses
Selling, general and administrative	$ 12,141	$ 7,961	$ 35,911	$ 20,893
Research and development	3,891	4,214	11,874	13,075
Change in fair value of contingent earnout		19		12
Total operating expenses	16,032	12,194	47,785	33,980
Loss from operations	(15,112)	(11,268)	(44,683)	(31,482)
Software
Segment Reporting Information [Line Items]
Revenue	2,051	1,701	5,986	5,140
Cost of sales	653	578	1,938	1,754
Gross profit	$ 1,398	$ 1,123	$ 4,048	$ 3,386
Gross margin	68%	66%	68%	66%
Operating expenses
Selling, general and administrative	$ 445	$ 534	$ 1,482	$ 1,507
Research and development	437	419	1,322	1,235
Total operating expenses	882	953	2,804	2,742
Loss from operations	$ 516	$ 170	$ 1,244	$ 644

Segment Information - Segment A

Segment Information - Segment Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Segment Reporting Asset Reconciling Item [Line Items]
Total assets	$ 142,940	$ 115,499
Product
Segment Reporting Asset Reconciling Item [Line Items]
Total assets	132,245	104,588
Software
Segment Reporting Asset Reconciling Item [Line Items]
Total assets	$ 10,695	$ 10,911

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net loss attributable to common stock holders	$ (15,539)	$ (15,137)	$ (15,522)	$ (12,733)	$ (11,149)	$ (10,906)	$ (46,198)	$ (34,788)
Denominator:
Weighted-average shares outstanding - basic	33,116,536			1,232,921			28,688,018	1,218,815
Weighted-average shares outstanding - diluted	33,116,536			1,232,921			28,688,018	1,218,815
Net loss per share - basic	$ (0.47)			$ (10.33)			$ (1.61)	$ (28.54)
Net loss per share - diluted	$ (0.47)			$ (10.33)			$ (1.61)	$ (28.54)